Arbutus shareholders approve 3.5M share increase to 2016 equity incentive plan

Arbutus Biopharma Corp

Shareholders approved amendment to 2016 Omnibus Plan, increasing authorized shares by 3,500,000 (85.6M for, 9.0M against).
All six director nominees elected: Frank Torti, William Collier, Daniel Burgess, Richard Henriques, Keith Manchester, James Meyers.
Non-binding advisory vote on named executive officer compensation approved (85.6M for, 8.2M against, 1.1M abstain).
Ratification of Ernst & Young as independent auditor for 2023 approved (125.7M for, 0.8M against).

Key facts

Extracted from this filing and checked against the source text.

Shareholder Votes SEC 8-K Item 5.07 confidence 0.99

Arbutus Biopharma Corp shareholders approved To elect the six director nominees named in the Proxy Statement/Circular each to serve until the 2024 Annual General Meeting of Shareholders or until his qualified successor has been duly elected or appointed at the 2023-05-30 meeting.

Proposal: director election
Outcome: passed
Meeting: 2023-05-30

Exact text from the filing

Proposal 1. To elect the six director nominees named in the Proxy Statement/Circular each to serve until the 2024 Annual General Meeting of Shareholders or until his qualified successor has been duly elected or appointed: Nominee Votes For Votes Withheld Broker Non-Votes Frank Torti, M.D. 90,586,551 4,232,931 32,000,882 William H. Collier 92,373,962 2,445,520 32,000,882 Daniel Burgess 82,787,752 12,031,730 32,000,882 Richard C. Henriques 92,385,485 2,433,997 32,000,882 Keith Manchester, M.D. 72,493,891 22,325,591 32,000,882 James Meyers 92,126,144 2,693,338 32,000,882

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.99

Arbutus Biopharma Corp shareholders approved To ratify the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023 at the 2023-05-30 meeting.

Proposal: auditor ratification
Outcome: passed
Meeting: 2023-05-30

Exact text from the filing

Proposal 4. To ratify the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023: Votes For Votes Against Votes Abstained Broker Non-Votes 125,655,064 786,900 378,400 —

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.99

Arbutus Biopharma Corp shareholders approved To approve an amendment to the 2016 Plan to (a) increase the aggregate number of common shares authorized for issuance thereunder by 3,500,000 common shares and (b) increase the aggregate number of common shares that may be issued pursuant to incentive stock options granted thereunder by 3,500,000 c at the 2023-05-30 meeting.

Proposal: equity plan
Outcome: passed
Meeting: 2023-05-30

Exact text from the filing

Proposal 2. To approve an amendment to the 2016 Plan to (a) increase the aggregate number of common shares authorized for issuance thereunder by 3,500,000 common shares and (b) increase the aggregate number of common shares that may be issued pursuant to incentive stock options granted thereunder by 3,500,000 common shares: Votes For Votes Against Votes Abstained Broker Non-Votes 85,636,644 8,972,164 210,674 32,000,882

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.99

Arbutus Biopharma Corp shareholders approved To approve, by non-binding advisory vote, the compensation of the Company’s named executive officers as disclosed in the Proxy Statement/Circular at the 2023-05-30 meeting.

Proposal: say on pay
Outcome: passed
Meeting: 2023-05-30

Exact text from the filing

Proposal 3. To approve, by non-binding advisory vote, the compensation of the Company’s named executive officers as disclosed in the Proxy Statement/Circular: Votes For Votes Against Votes Abstained Broker Non-Votes 85,552,303 8,211,196 1,055,983 32,000,882

View on SEC.gov

499 shareholder votes filed in the last 30 days. Browse all shareholder votes →

Arbutus Biopharma Corp filing history →

Source: SEC EDGAR

accession 0001447028-23-000052

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.